CA3146385A1 - Peptide conjugates of microtubule-targeting agents as therapeutics - Google Patents
Peptide conjugates of microtubule-targeting agents as therapeutics Download PDFInfo
- Publication number
- CA3146385A1 CA3146385A1 CA3146385A CA3146385A CA3146385A1 CA 3146385 A1 CA3146385 A1 CA 3146385A1 CA 3146385 A CA3146385 A CA 3146385A CA 3146385 A CA3146385 A CA 3146385A CA 3146385 A1 CA3146385 A1 CA 3146385A1
- Authority
- CA
- Canada
- Prior art keywords
- nrcic
- cancer
- compound
- rbl
- 0ral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962872638P | 2019-07-10 | 2019-07-10 | |
| US62/872,638 | 2019-07-10 | ||
| US202063041324P | 2020-06-19 | 2020-06-19 | |
| US63/041,324 | 2020-06-19 | ||
| PCT/US2020/041348 WO2021007402A1 (en) | 2019-07-10 | 2020-07-09 | Peptide conjugates of microtubule-targeting agents as therapeutics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3146385A1 true CA3146385A1 (en) | 2021-01-14 |
Family
ID=71944331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3146385A Pending CA3146385A1 (en) | 2019-07-10 | 2020-07-09 | Peptide conjugates of microtubule-targeting agents as therapeutics |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11555019B2 (https=) |
| EP (1) | EP3996749A1 (https=) |
| JP (1) | JP7675060B2 (https=) |
| KR (1) | KR20220051332A (https=) |
| CN (1) | CN114302744B (https=) |
| AU (1) | AU2020311925A1 (https=) |
| BR (1) | BR112022000297A2 (https=) |
| CA (1) | CA3146385A1 (https=) |
| CL (1) | CL2022000043A1 (https=) |
| CO (1) | CO2022001315A2 (https=) |
| CR (1) | CR20220057A (https=) |
| EC (1) | ECSP22010121A (https=) |
| IL (1) | IL289659B1 (https=) |
| MX (1) | MX2022000450A (https=) |
| MY (1) | MY209459A (https=) |
| PE (1) | PE20220485A1 (https=) |
| PH (1) | PH12022550037A1 (https=) |
| TW (1) | TW202116356A (https=) |
| WO (1) | WO2021007402A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200121800A (ko) | 2018-01-05 | 2020-10-26 | 싸이브렉사 1, 인크. | 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법 |
| MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| US11555019B2 (en) | 2019-07-10 | 2023-01-17 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
| CN116940691A (zh) | 2021-01-08 | 2023-10-24 | 赛博克萨2公司 | 用于制备缀合物连接部分的方法 |
| MX2024005938A (es) * | 2021-11-17 | 2024-08-14 | Cybrexa 4 Inc | Conjugados peptídicos de inhibidores de tubulina peptídica como agentes terapéuticos. |
Family Cites Families (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5658920A (en) | 1991-01-16 | 1997-08-19 | Daiichi Pharmaceutical Co., Ltd. | Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound |
| US6504029B1 (en) | 1995-04-10 | 2003-01-07 | Daiichi Pharmaceutical Co., Ltd. | Condensed-hexacyclic compounds and a process therefor |
| EP0841924B1 (en) | 1995-08-02 | 2002-10-02 | Newcastle University Ventures Limited | Benzimidazole compounds |
| DE69707860T2 (de) | 1996-04-26 | 2002-04-11 | Daiichi Pharmaceutical Co., Ltd. | Verfahren zur herstellung von tetrahydroindolizinen |
| TW409058B (en) | 1996-06-06 | 2000-10-21 | Daiichi Seiyaku Co | Method for preparation of a drug complex |
| TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| IN189180B (https=) | 1997-07-09 | 2003-01-04 | Chong Kun Dang Corp | |
| MY132496A (en) | 1998-05-11 | 2007-10-31 | Vertex Pharma | Inhibitors of p38 |
| EA003398B1 (ru) | 1998-05-22 | 2003-04-24 | Дайити Фармасьютикал Ко., Лтд. | Лекарственный комплекс c полимерным носителем |
| CN1191093C (zh) | 1998-10-30 | 2005-03-02 | 第一制药株式会社 | Dds化合物及其测定方法 |
| IL142917A0 (en) | 1998-11-03 | 2002-04-21 | Basf Ag | Substituted 2-phenylbenzimidazoles, the production thereof and their use |
| US6495541B1 (en) | 1999-01-11 | 2002-12-17 | Agouron Pharmaceuticals, Inc. | Tricyclic inhibitors of poly(ADP-ribose) polymerases |
| DE19920936A1 (de) | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
| ECSP003637A (es) | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
| US6699876B2 (en) | 1999-11-18 | 2004-03-02 | Les Laboratoires Servier | Camptothecin analogue compounds |
| CA2396513A1 (en) | 1999-12-13 | 2001-06-14 | Yanzhi Zhang | Pseudomycin phosphate prodrugs |
| US6844318B2 (en) * | 2000-03-15 | 2005-01-18 | Bristol Myers Squibb Pharma Company | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
| AU2001271037A1 (en) | 2000-07-13 | 2002-01-30 | Daiichi Pharmaceutical Co., Ltd. | Pharmaceutical compositions containing dds compounds |
| US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| US6441163B1 (en) * | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US7771727B2 (en) | 2002-03-01 | 2010-08-10 | The Administrators Of The Tulane Educational Fund | Conjugates of therapeutic or cytotoxic agents and biologically active peptides |
| GEP20074230B (en) | 2002-03-20 | 2007-11-12 | Bristol Myers Squibb Co | Phosphate prodrugs of fluorooxindoles |
| DE60335359D1 (de) | 2002-04-30 | 2011-01-27 | Kudos Pharm Ltd | Phthalazinonderivate |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| CA2520997A1 (en) | 2003-03-31 | 2004-10-14 | Stacie Sara Canan-Koch | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
| CN1816356A (zh) | 2003-05-14 | 2006-08-09 | 免疫原公司 | 药物缀合物组合物 |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| MXPA05011811A (es) | 2003-05-20 | 2006-02-17 | Immunogen Inc | Agentes citotoxicos mejorados que comprenden nuevos maitansinoides. |
| US7531530B2 (en) | 2003-07-25 | 2009-05-12 | Cancer Research Technology Limited | Therapeutic compounds |
| GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| PL2305221T3 (pl) | 2003-12-01 | 2015-11-30 | Kudos Pharm Ltd | Inhibitory naprawy uszkodzeń DNA w leczeniu raka |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| CN101098854B (zh) | 2004-07-23 | 2012-12-05 | 恩多塞特公司 | 二价连接体及其轭合物 |
| PT1794163E (pt) | 2004-09-22 | 2010-03-01 | Pfizer | Método para a preparação de inibidores de poli(adpribose)- polimerases |
| MX2007003314A (es) | 2004-09-22 | 2007-08-06 | Pfizer | Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas. |
| ATE551345T1 (de) | 2004-09-22 | 2012-04-15 | Pfizer | Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on |
| US8603483B2 (en) | 2004-12-09 | 2013-12-10 | Janssen Biotech, Inc. | Anti-integrin immunoconjugates, methods and uses |
| WO2006078816A2 (en) | 2005-01-18 | 2006-07-27 | The Board Of Governors For Higher Education | Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide |
| US7301019B2 (en) | 2005-01-21 | 2007-11-27 | Immunogen, Inc. | Method for the preparation of maytansinoid esters |
| ES2503719T3 (es) | 2005-02-11 | 2014-10-07 | Immunogen, Inc. | Procedimiento para preparar conjugados de anticuerpos y de maitansinoides |
| US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| KR20070120156A (ko) | 2005-04-15 | 2007-12-21 | 이뮤노젠 아이엔씨 | 종양에서 이종 또는 혼성 세포 집단의 제거 방법 |
| CA3000520C (en) | 2005-08-24 | 2023-04-04 | Immunogen, Inc. | Process for preparing antibody maytansinoid conjugates |
| JP5227796B2 (ja) | 2005-09-29 | 2013-07-03 | アボット・ラボラトリーズ | ２位においてフェニルによって置換された１ｈ−ベンズイミダゾール−４−カルボキサミドは強力なｐａｒｐ阻害薬である |
| EP1945647B9 (en) | 2005-11-08 | 2012-11-14 | Immunogen, Inc. | Processes for preparation of maytansinol |
| EP1976515A2 (en) | 2006-01-17 | 2008-10-08 | Abbott Laboratories | Combination therapy with parp inhibitors |
| BRPI0710407A2 (pt) | 2006-05-04 | 2012-04-17 | Genentech Inc | poliptìdeos, peixes-zebra transgênicos, modelos de sistemas, métodos de identificação de compostos, de identificação de agentes, métodos de tratamento de disfunções relativas a apoptose, método de identificação de agentes de prevenção ou redução da apoptose, composição de aumento da apoptose, composições de redução ou prevenção de apoptose, composição de apoptose, método de detecção, kits e artigo industrializado |
| UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
| JP4611444B2 (ja) | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール |
| WO2008114114A2 (en) | 2007-03-16 | 2008-09-25 | Pfizer Products Inc. | Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition |
| CN101784565B (zh) | 2007-06-25 | 2014-12-10 | 恩多塞特公司 | 含有亲水性间隔区接头的共轭物 |
| US8067613B2 (en) | 2007-07-16 | 2011-11-29 | Abbott Laboratories | Benzimidazole poly(ADP ribose)polymerase inhibitors |
| PL2187965T3 (pl) | 2007-08-17 | 2020-05-18 | Purdue Research Foundation | Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania |
| SG189817A1 (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
| PE20100083A1 (es) | 2008-06-05 | 2010-02-17 | Janssen Pharmaceutica Nv | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar |
| US20160095939A1 (en) | 2014-10-07 | 2016-04-07 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
| SG10201810743WA (en) | 2009-06-03 | 2018-12-28 | Immunogen Inc | Conjugation methods |
| WO2011066418A1 (en) | 2009-11-25 | 2011-06-03 | Academia Sinica | The tumor-selective anti-cancer prodrug bqc-g |
| EP4166558A1 (en) | 2010-02-12 | 2023-04-19 | Pfizer Inc. | Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one |
| CA2790577A1 (en) | 2010-02-25 | 2011-09-01 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
| SG184324A1 (en) | 2010-03-31 | 2012-11-29 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| ES2584381T3 (es) | 2010-05-05 | 2016-09-27 | Prolynx Llc | Liberación controlada de compuestos activos desde conjugados macromoleculares |
| EP4321168A3 (en) | 2010-07-13 | 2024-04-24 | Yale University, Inc. | Environmentally sensitive compositions |
| AU2011289279B2 (en) | 2010-08-13 | 2016-11-03 | University Of Rhode Island Board Of Trustees | Liposome compositions and methods of use thereof |
| AU2011323316B2 (en) | 2010-11-03 | 2016-02-25 | Immunogen, Inc. | Cytotoxic agents comprising new ansamitocin derivatives |
| ME03353B (me) | 2011-03-29 | 2019-10-20 | Immunogen Inc | Priprema konjugata antitela i majtanzinoida jednostepenim postupkom |
| MY171008A (en) | 2011-03-29 | 2019-09-23 | Immunogen Inc | Preparation of maytansinoid antibody conjugates by a one-step process |
| BR112014009050B1 (pt) | 2011-10-14 | 2022-06-21 | Medimmune Limited | Conjugado anticorpo-fármaco de pirrolbenzodiazepinas, composição farmacêutica que compreende o mesmo, bem como compostos de pirrolbenzodiazepinas |
| ES2773710T3 (es) | 2012-10-11 | 2020-07-14 | Daiichi Sankyo Co Ltd | Enlazadores para conjugados de anticuerpo - fármaco |
| WO2014061277A1 (ja) | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート |
| EP2911701A4 (en) | 2012-10-23 | 2016-06-08 | Univ Johns Hopkins | Novel self-assembling drug amphiphiles and methods for synthesis and application |
| US9919059B2 (en) | 2012-12-10 | 2018-03-20 | Massachusetts Institute Of Technology | Multistage nanoparticle drug delivery system for the treatment of solid tumors |
| EP2927227A4 (en) | 2013-01-03 | 2015-12-30 | Celltrion Inc | ANTIBODY CONCENTRATOR REMEDY CONJUGATE, METHOD OF MANUFACTURING THEREOF, AND ANTIBODY TOGETHER THEREWITH |
| EP3566750A3 (en) | 2013-02-28 | 2020-04-08 | ImmunoGen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| KR102442906B1 (ko) | 2013-12-19 | 2022-09-14 | 씨젠 인크. | 표적화된-약물 컨쥬게이트와 함께 사용되는 메틸렌 카바메이트 링커 |
| CN105917007A (zh) | 2014-01-16 | 2016-08-31 | 克洛维斯肿瘤有限公司 | Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途 |
| HUE045065T2 (hu) | 2014-01-31 | 2019-12-30 | Novartis Ag | TIM-3 antitest molekulák és felhasználásaik |
| JP2017114763A (ja) | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗ｃｄ９８抗体−薬物コンジュゲート |
| KR102445502B1 (ko) | 2014-04-10 | 2022-09-21 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| EP3130608B1 (en) | 2014-04-10 | 2019-09-04 | Daiichi Sankyo Co., Ltd. | (anti-her2 antibody)-drug conjugate |
| WO2016004043A1 (en) | 2014-06-30 | 2016-01-07 | Blend Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
| AU2015305696B2 (en) | 2014-08-22 | 2019-08-29 | Pharma& Schweiz Gmbh | High dosage strength tablets of rucaparib |
| JP6214790B2 (ja) | 2014-09-16 | 2017-10-18 | イース チャーム リミテッド | 抗ｅｇｆｒ抗体および同抗体の使用法 |
| US10413615B2 (en) | 2014-11-19 | 2019-09-17 | Immunogen, Inc. | Process for preparing cell-binding agent-cytotoxic agent conjugates |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| KR102407261B1 (ko) | 2015-02-27 | 2022-07-06 | 서울대학교산학협력단 | 나노 항암제형 및 그 제조 방법 |
| MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
| US11160871B2 (en) * | 2015-10-28 | 2021-11-02 | Tarveda Therapeutics, Inc. | SSTR-targeted conjugates and particles and formulations thereof |
| RS60237B1 (sr) | 2015-11-24 | 2020-06-30 | Theravance Biopharma R&D Ip Llc | Prolekovi jak inhibitornih jedinjenja za lečenje gastorintestinalne inflamatorne bolesti |
| KR102498258B1 (ko) | 2016-01-20 | 2023-02-10 | 삼성디스플레이 주식회사 | 표시 장치 |
| US20170267727A1 (en) | 2016-03-04 | 2017-09-21 | Lehigh University | Conjugates of pH Low Insertion Peptide and Monomethyl Auristatins in the Treatment of Solid Tumors |
| EP3426301A4 (en) | 2016-03-08 | 2019-11-06 | Los Gatos Pharmaceuticals, Inc. | VERBUNDNANOPARTICLES AND USES THEREOF |
| EP3442592A4 (en) * | 2016-04-13 | 2019-11-27 | Tarveda Therapeutics, Inc. | NEUROTENSIN RECEPTOR BINDING CONJUGATES AND FORMULATIONS THEREOF |
| GB201608885D0 (en) | 2016-05-20 | 2016-07-06 | Univ Birmingham | Treatment |
| WO2017210608A1 (en) | 2016-06-02 | 2017-12-07 | Yale University | Compositions and methods for targeting and treating homologous recombination-deficient tumors |
| EP3491007A4 (en) * | 2016-07-29 | 2020-04-22 | Memorial Sloan-Kettering Cancer Center | RADIOACTIVELY MARKED LIGANDS FOR TARGETED PET / SPECT IMAGING AND METHOD FOR THE USE THEREOF |
| CA3032775C (en) | 2016-08-16 | 2024-01-23 | National Institute Of Advanced Industrial Science And Technology | Malignant tumor target peptide |
| CA3037241A1 (en) * | 2016-09-22 | 2018-03-29 | Rhode Island Council On Postsecondary Education | Fluorescent compound comprising a fluorophore conjugated to a ph-triggered polypeptide |
| CA3044898C (en) | 2016-11-25 | 2022-04-05 | Mabwell (shanghai) Bioscience Co., Ltd. | Di-substituted maleic amide linker for antibody-drug conjugating and preparation method and use thereof |
| WO2018118015A1 (en) | 2016-12-19 | 2018-06-28 | Morehouse School Of Medicine | Compositions and methods for treating diseases by inhibiting exosome release |
| WO2018227132A1 (en) | 2017-06-09 | 2018-12-13 | Rhode Island Council On Postsecondary Education | Linked and other ph-triggered compounds |
| CA3074208C (en) | 2017-08-31 | 2023-10-03 | Daiichi Sankyo Company, Limited | Novel method for producing antibody-drug conjugate |
| KR20200121800A (ko) | 2018-01-05 | 2020-10-26 | 싸이브렉사 1, 인크. | 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법 |
| MX2020007442A (es) | 2018-01-12 | 2020-09-14 | Prolynx Llc | Protocolo para minimizar la toxicidad de dosificaciones de combinacion y agente formador de imagen para verificacion. |
| SG11202010496WA (en) | 2018-05-18 | 2020-12-30 | Daiichi Sankyo Co Ltd | Anti-muc1 antibody-drug conjugate |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| CN109232719B (zh) | 2018-09-21 | 2021-06-29 | 中国科学院理化技术研究所 | 一种pH响应的抗菌肽及其制备方法和应用 |
| EP3917528A4 (en) | 2019-01-28 | 2022-12-28 | University of Rhode Island Board of Trustees | Phlip® targeted delivery of potent cytotoxic compounds |
| MX2021011812A (es) | 2019-03-29 | 2021-10-22 | Medimmune Ltd | Compuestos y conjugados de estos. |
| MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| US11555019B2 (en) | 2019-07-10 | 2023-01-17 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
| CN116940691A (zh) | 2021-01-08 | 2023-10-24 | 赛博克萨2公司 | 用于制备缀合物连接部分的方法 |
| CN117897175A (zh) | 2021-04-29 | 2024-04-16 | 美商斯布雷克萨二号公司 | 拓扑异构酶i抑制剂的肽缀合物的给药方案 |
| MX2024005938A (es) | 2021-11-17 | 2024-08-14 | Cybrexa 4 Inc | Conjugados peptídicos de inhibidores de tubulina peptídica como agentes terapéuticos. |
-
2020
- 2020-07-09 US US16/924,445 patent/US11555019B2/en active Active
- 2020-07-09 EP EP20750936.5A patent/EP3996749A1/en active Pending
- 2020-07-09 BR BR112022000297A patent/BR112022000297A2/pt unknown
- 2020-07-09 AU AU2020311925A patent/AU2020311925A1/en active Pending
- 2020-07-09 WO PCT/US2020/041348 patent/WO2021007402A1/en not_active Ceased
- 2020-07-09 MY MYPI2022000121A patent/MY209459A/en unknown
- 2020-07-09 TW TW109123266A patent/TW202116356A/zh unknown
- 2020-07-09 JP JP2022501186A patent/JP7675060B2/ja active Active
- 2020-07-09 CN CN202080057629.3A patent/CN114302744B/zh active Active
- 2020-07-09 MX MX2022000450A patent/MX2022000450A/es unknown
- 2020-07-09 CR CR20220057A patent/CR20220057A/es unknown
- 2020-07-09 KR KR1020227004520A patent/KR20220051332A/ko active Pending
- 2020-07-09 CA CA3146385A patent/CA3146385A1/en active Pending
- 2020-07-09 PE PE2022000038A patent/PE20220485A1/es unknown
- 2020-07-09 PH PH1/2022/550037A patent/PH12022550037A1/en unknown
-
2022
- 2022-01-06 IL IL289659A patent/IL289659B1/en unknown
- 2022-01-07 CL CL2022000043A patent/CL2022000043A1/es unknown
- 2022-02-09 CO CONC2022/0001315A patent/CO2022001315A2/es unknown
- 2022-02-09 EC ECSENADI202210121A patent/ECSP22010121A/es unknown
-
2023
- 2023-01-11 US US18/152,987 patent/US12234212B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220051332A (ko) | 2022-04-26 |
| IL289659B1 (en) | 2026-01-01 |
| AU2020311925A1 (en) | 2022-02-03 |
| US12234212B2 (en) | 2025-02-25 |
| JP2022541747A (ja) | 2022-09-27 |
| JP7675060B2 (ja) | 2025-05-12 |
| US20210009536A1 (en) | 2021-01-14 |
| US11555019B2 (en) | 2023-01-17 |
| BR112022000297A2 (pt) | 2022-03-15 |
| ECSP22010121A (es) | 2022-05-31 |
| EP3996749A1 (en) | 2022-05-18 |
| MX2022000450A (es) | 2022-04-25 |
| CR20220057A (es) | 2022-07-19 |
| CL2022000043A1 (es) | 2022-08-19 |
| CN114302744A (zh) | 2022-04-08 |
| CO2022001315A2 (es) | 2022-05-10 |
| MY209459A (en) | 2025-07-09 |
| PE20220485A1 (es) | 2022-04-04 |
| PH12022550037A1 (en) | 2023-04-12 |
| TW202116356A (zh) | 2021-05-01 |
| CN114302744B (zh) | 2025-08-26 |
| US20240067616A1 (en) | 2024-02-29 |
| WO2021007402A1 (en) | 2021-01-14 |
| IL289659A (en) | 2022-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7673041B2 (ja) | 治療薬としての細胞毒素のペプチドコンジュゲート | |
| TWI820077B (zh) | 治療涉及酸性或缺氧性患病組織之疾病之化合物、組合物及方法 | |
| US12234212B2 (en) | Peptide conjugates of microtubule-targeting agents as therapeutics | |
| JP2022541749A5 (https=) | ||
| US20230416331A1 (en) | Peptide conjugates of peptidic tubulin inhibitors as therapeutics | |
| EA051761B1 (ru) | Пептидные конъюгаты агентов, нацеленных на микротрубочки, в качестве терапевтических средств | |
| WO2022155172A1 (en) | Peptide conjugates of therapeutics | |
| TWI918605B (zh) | 作為治療劑之細胞毒素之肽結合物 | |
| EA051826B1 (ru) | Пептидные конъюгаты цитотоксинов в качестве терапевтических средств |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240705 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20240705 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20241030 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250114 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250127 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250127 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250127 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20250324 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250324 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250505 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250702 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250702 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251127 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260325 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260326 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260326 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260326 |